Mirum Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 11.000 million. Operating loss was USD 37.401 million compared to USD 23.597 million a year ago. Net loss was USD 43.894 million compared to USD 23.251 million a year ago. Basic loss per share from continuing operations was USD 1.45 compared to USD 0.93 a year ago. For the half year, sales was USD 11.000 million. Operating loss was USD 85.014 million compared to USD 45.629 million a year ago. Net loss was USD 94.426 million compared to USD 44.561 million a year ago. Basic loss per share from continuing operations was USD 3.13 compared to USD 1.79 a year ago.